Suven Pharmaceuticals Ltd
NSE:SUVENPHAR

Watchlist Manager
Suven Pharmaceuticals Ltd Logo
Suven Pharmaceuticals Ltd
NSE:SUVENPHAR
Watchlist
Price: 1 261.85 INR -1.97%
Market Cap: 321.2B INR
Have any thoughts about
Suven Pharmaceuticals Ltd?
Write Note

Intrinsic Value

The intrinsic value of one SUVENPHAR stock under the Base Case scenario is 402.41 INR. Compared to the current market price of 1 261.85 INR, Suven Pharmaceuticals Ltd is Overvalued by 68%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

SUVENPHAR Intrinsic Value
402.41 INR
Overvaluation 68%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Suven Pharmaceuticals Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for SUVENPHAR cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about SUVENPHAR?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Suven Pharmaceuticals Ltd

Provide an overview of the primary business activities
of Suven Pharmaceuticals Ltd.

What unique competitive advantages
does Suven Pharmaceuticals Ltd hold over its rivals?

What risks and challenges
does Suven Pharmaceuticals Ltd face in the near future?

Has there been any significant insider trading activity
in Suven Pharmaceuticals Ltd recently?

Summarize the latest earnings call
of Suven Pharmaceuticals Ltd.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Suven Pharmaceuticals Ltd.

Provide P/S
for Suven Pharmaceuticals Ltd.

Provide P/E
for Suven Pharmaceuticals Ltd.

Provide P/OCF
for Suven Pharmaceuticals Ltd.

Provide P/FCFE
for Suven Pharmaceuticals Ltd.

Provide P/B
for Suven Pharmaceuticals Ltd.

Provide EV/S
for Suven Pharmaceuticals Ltd.

Provide EV/GP
for Suven Pharmaceuticals Ltd.

Provide EV/EBITDA
for Suven Pharmaceuticals Ltd.

Provide EV/EBIT
for Suven Pharmaceuticals Ltd.

Provide EV/OCF
for Suven Pharmaceuticals Ltd.

Provide EV/FCFF
for Suven Pharmaceuticals Ltd.

Provide EV/IC
for Suven Pharmaceuticals Ltd.

Show me price targets
for Suven Pharmaceuticals Ltd made by professional analysts.

What are the Revenue projections
for Suven Pharmaceuticals Ltd?

How accurate were the past Revenue estimates
for Suven Pharmaceuticals Ltd?

What are the Net Income projections
for Suven Pharmaceuticals Ltd?

How accurate were the past Net Income estimates
for Suven Pharmaceuticals Ltd?

What are the EPS projections
for Suven Pharmaceuticals Ltd?

How accurate were the past EPS estimates
for Suven Pharmaceuticals Ltd?

What are the EBIT projections
for Suven Pharmaceuticals Ltd?

How accurate were the past EBIT estimates
for Suven Pharmaceuticals Ltd?

Compare the revenue forecasts
for Suven Pharmaceuticals Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Suven Pharmaceuticals Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Suven Pharmaceuticals Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Suven Pharmaceuticals Ltd compared to its peers.

Compare the P/E ratios
of Suven Pharmaceuticals Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Suven Pharmaceuticals Ltd with its peers.

Analyze the financial leverage
of Suven Pharmaceuticals Ltd compared to its main competitors.

Show all profitability ratios
for Suven Pharmaceuticals Ltd.

Provide ROE
for Suven Pharmaceuticals Ltd.

Provide ROA
for Suven Pharmaceuticals Ltd.

Provide ROIC
for Suven Pharmaceuticals Ltd.

Provide ROCE
for Suven Pharmaceuticals Ltd.

Provide Gross Margin
for Suven Pharmaceuticals Ltd.

Provide Operating Margin
for Suven Pharmaceuticals Ltd.

Provide Net Margin
for Suven Pharmaceuticals Ltd.

Provide FCF Margin
for Suven Pharmaceuticals Ltd.

Show all solvency ratios
for Suven Pharmaceuticals Ltd.

Provide D/E Ratio
for Suven Pharmaceuticals Ltd.

Provide D/A Ratio
for Suven Pharmaceuticals Ltd.

Provide Interest Coverage Ratio
for Suven Pharmaceuticals Ltd.

Provide Altman Z-Score Ratio
for Suven Pharmaceuticals Ltd.

Provide Quick Ratio
for Suven Pharmaceuticals Ltd.

Provide Current Ratio
for Suven Pharmaceuticals Ltd.

Provide Cash Ratio
for Suven Pharmaceuticals Ltd.

What is the historical Revenue growth
over the last 5 years for Suven Pharmaceuticals Ltd?

What is the historical Net Income growth
over the last 5 years for Suven Pharmaceuticals Ltd?

What is the current Free Cash Flow
of Suven Pharmaceuticals Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Suven Pharmaceuticals Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Suven Pharmaceuticals Ltd

Current Assets 11.7B
Cash & Short-Term Investments 6.7B
Receivables 1.9B
Other Current Assets 3.1B
Non-Current Assets 13.4B
Long-Term Investments 1.4B
PP&E 8.9B
Intangibles 2.7B
Other Non-Current Assets 315.9m
Current Liabilities 2.4B
Accounts Payable 652.8m
Other Current Liabilities 1.7B
Non-Current Liabilities 2.9B
Long-Term Debt 306.6m
Other Non-Current Liabilities 2.6B
Efficiency

Earnings Waterfall
Suven Pharmaceuticals Ltd

Revenue
9.6B INR
Cost of Revenue
-3.7B INR
Gross Profit
5.9B INR
Operating Expenses
-3.3B INR
Operating Income
2.6B INR
Other Expenses
-213.3m INR
Net Income
2.4B INR

Free Cash Flow Analysis
Suven Pharmaceuticals Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

In Q2 FY '25, Suven Pharma reported a 12% revenue increase to INR 2.58 billion, boosted by the acquisition of Sapala. The pharma CDMO segment surged by 40% year-on-year, with projected full-year growth. Adjusted EBITDA improved to INR 1.11 billion, with margins at 43.3%. Notably, Cohance's performance revealed a 13% decline in revenue, attributed to timing in shipments, but overall growth is anticipated. Suven's commitment to R&D and strategic mergers hints at robust growth, aiming to double the business within five years. Full-year platform growth is expected compared to FY '24, with significant improvements in profitability as well【4:1†source】.

What is Earnings Call?
Fundamental Scores

SUVENPHAR Profitability Score
Profitability Due Diligence

Suven Pharmaceuticals Ltd's profitability score is 62/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Operating Income
Positive 3-Year Average ROE
Positive 3-Year Average ROIC
62/100
Profitability
Score

Suven Pharmaceuticals Ltd's profitability score is 62/100. The higher the profitability score, the more profitable the company is.

SUVENPHAR Solvency Score
Solvency Due Diligence

Suven Pharmaceuticals Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
99/100
Solvency
Score

Suven Pharmaceuticals Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

SUVENPHAR Price Targets Summary
Suven Pharmaceuticals Ltd

Wall Street analysts forecast SUVENPHAR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SUVENPHAR is 1 356.6 INR with a low forecast of 1 343.3 INR and a high forecast of 1 396.5 INR.

Lowest
Price Target
1 343.3 INR
6% Upside
Average
Price Target
1 356.6 INR
8% Upside
Highest
Price Target
1 396.5 INR
11% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for SUVENPHAR?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for SUVENPHAR is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

SUVENPHAR Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Suven Pharmaceuticals Ltd Logo
Suven Pharmaceuticals Ltd

Country

India

Industry

Pharmaceuticals

Market Cap

322.6B INR

Dividend Yield

0%

Description

Suven Pharmaceuticals Ltd. manufactures chemical products. The company is headquartered in Hyderabad, Telangana and currently employs 1,193 full-time employees. The company went IPO on 2020-03-09. The firm operates through Pharmaceuticals Manufacturing and Services segment. Its geographical segments include India, the United States, Europe and Rest of the World. In India, the Company sells bulk drugs and intermediates, fine chemicals and services. In the United States, the Company sells intermediates and services. In Europe, the Company sells bulk drugs and intermediates. In Rest of the World, the Company sells bulk drugs, intermediates and services. The Company’s wholly owned subsidiary is Suven Pharma Inc.

Contact

TELANGANA
Hyderabad
# 8-2-334, Sde Serene Chambers, 3Rd Floor Avenue 7, Road No. 5, Banjara Hills
www.suvenpharm.com

IPO

2020-03-09

Employees

1 193

Officers

Executive Chairman
Mr. Vivek Sharma CPA
Chief Executive Officer
Dr. Sudhir Kumar Singh Ph.D.
Chief Financial Officer
Mr. Himanshu Agarwal
Head of Investor Relations
Ms. Cyndrella Carvalho
Company Secretary & Compliance Officer
Mr. Kundan Kumar Jha
Chief Human Resources Officer
Mr. Gaurav Narain Bahadur
Show More
MD & Director
Dr. Vetukuri Venkata Naga Kali Vara Prasada Raju
Chief Strategy Officer
Mr. Subba Raju Komaravolu
Vice President of Corporate Affairs
Mr. Sunder Venkatraman
Show Less

See Also

Discover More
What is the Intrinsic Value of one SUVENPHAR stock?

The intrinsic value of one SUVENPHAR stock under the Base Case scenario is 402.41 INR.

Is SUVENPHAR stock undervalued or overvalued?

Compared to the current market price of 1 261.85 INR, Suven Pharmaceuticals Ltd is Overvalued by 68%.

Back to Top